The FDA is to review Sanofi/Regeneron's Dupixent as a treatment for asthma, a new use that could more than double its sales following its previous approval for eczema. Analysts predict peak annual ...

which Dupixent helps target by blocking certain immune signaling pathways. The injection is already approved for CSU in several other countries, including Japan and Brazil, and regulatory reviews ...

The FDA has approved the popular drug Dupixent (generic name, dupilumab) for adults and kids 12 and up with chronic spontaneous urticaria (CSU), a long-lasting itchy skin condition, when regular ...

The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with ...

Sanofi and Regeneron's eczema injection Dupixent looks set for approval later ... six-month Priority Review. Sanofi is in need of a big success after the FDA delayed a decision on arthritis ...

However, several Wall Street analysts compared the results to Sanofi SNY/Regeneron’s REGN blockbuster immunology drug Dupixent, which is also considered the standard of care in AD indication.

Given the priority review of the sBLA ... as well as safety data of Dupixent in its currently approved indications for adolescents like moderate-to-severe eczema (atopic dermatitis).

Dupixent is already approved for CSU in Japan, the United Arab Emirates (UAE) and Brazil. Submissions are currently under review with other regulatory authorities around the world including in the ...